Popular on TelAve
- ReClaim Opens Waitlist for Minimalist Android Launcher Designed to Reduce Screen Time - 245
- Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry - 144
- $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc - 132
- OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors - 127
- Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 123
- Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry - 120
- BEC Technologies Launches MX-340-IRD Hybrid Cellular+Satellite Gateway for Resilient IoT - 116
- Coinfiliate Launches Platform to Helps Shoppers Earn Cashback and Creators Earn Referral Rewards - 113
- SafecomLink 5G-AI-ALE: Automatic Link Establishment that Stays Active for the Life of the Link - 111
- Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers - 103
Similar on TelAve
- Hospital Direct Medical Equipment Company Seeing Growth in Used Refurbished Medical Equipment Sales
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Nashville
- Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms
- National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
- New England Consulting Partners Celebrates 25 Years of Turnaround Management Solutions
- RAS AP Consulting Releases Educational Resource to Help Organizations Prepare for IRS FIRE-to-IRIS Transition
- Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
- Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
- Electives Launches "Electives for Everyone," Making Live Expert-Led Learning Available to Every Employee
- Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
2025 R&D Spending And Intensity Benchmarks
TelAve News/10905878
VIRGINIA BEACH, Va. - TelAve -- Schonfeld & Associates, Inc. has released the latest edition of its annual study R&D Ratios & Budgets. The new research report covers R&D spending and intensity in fiscal 2025 by more than 2,700 individual publicly traded companies within 280 industries. R&D Intensity, a key performance indicator, expresses a company's investment in research and development relative to its revenue. It is defined as the ratio of R&D spending to revenue.
The pharmaceutical industry continues to be the biggest R&D investor in fiscal 2025 with budgets of drug companies increasing slightly to $195 billion. Software companies contributed a total of over $132 billion to this investment pool.
The biggest single R&D investor in 2025 was Amazon at over $108 billion, followed by Alphabet at $61 billion, and then Meta, Microsoft and Apple at over $31 billion each. Firms involved with digital content are investing much more heavily than those in more traditional arenas.
Pharmaceutical firms continued significant R&D spending in 2025. Merck, the top spender at $15.7 billion, is followed by Johnson & Johnson, Astrazeneca, AbbVie, Eli Lilly, Pfizer, and Novartis each spending over $10 billion. The biotech industry, led by Amgen, decreased R&D spending by nearly 8% to $36 billion. Electromedical apparatus makers, led by Medtronic, spent a total of over $3.5 billion, an increase of 2% over 2024.
More on TelAve News
R&D budgets of semiconductor makers grew to over $93 billion, an increase of over 13%. Nvidia had the largest R&D budget, $18 billion, a 43% increase from 2024. Major suppliers to the infrastructure of the Internet cloud continue robust R&D spending to remain competitive.
The 2025 R&D spending of the automotive industry, led by Stellantis, Toyota, Honda, Ford and General Motors each spending over $8 billion, was up over 24% from the 2024 total with industry revenues up over 2%.
R&D Ratios & Budgets is an essential reference presenting R&D spending and intensity information published annually by Schonfeld & Associates, Inc. The study is based on 10-K annual report information submitted to the U.S. Securities & Exchange Commission.
R&D Ratios & Budgets contains information for each of the over 2,700 individual publicly traded companies. Fiscal year 2025 revenue and R&D spending are listed as well as annual growth rates of each. R&D intensity for 2025 is presented along with the lowest and highest R&D Intensity ratio during the past five years. The range of values gives an insight into the stability of the firm's commitment to funding R&D as well as its direction.
More on TelAve News
The industry summary section within R&D Ratios & Budgets presents for each of 280 industries: total fiscal year 2025 revenue and R&D spending as well as annual growth rates of each. The industry R&D intensity ratio for 2025 is listed so that an individual company's value can be compared to the value for the industry as a whole and to answer the question: Is this company leading or lagging its peers in prioritizing innovation?
To allow for further investigation, two Excel datafiles are available for purchase along with the PDF report. Each contains five years of revenue, R&D spending and R&D intensity information. One file contains company data and the other industry information.
The 2026 edition of the R&D Ratios & Budgets PDF study is $395 and the study along with Excel datafiles is $495. Contact Schonfeld & Associates, Inc., 1932 Terramar Lane, Virginia Beach, VA 23456. Call for more information or to place an order: 800-205-0030 or visit https://www.saibooks.com/product/r-d-ratios-budgets-2 for immediate download.
The pharmaceutical industry continues to be the biggest R&D investor in fiscal 2025 with budgets of drug companies increasing slightly to $195 billion. Software companies contributed a total of over $132 billion to this investment pool.
The biggest single R&D investor in 2025 was Amazon at over $108 billion, followed by Alphabet at $61 billion, and then Meta, Microsoft and Apple at over $31 billion each. Firms involved with digital content are investing much more heavily than those in more traditional arenas.
Pharmaceutical firms continued significant R&D spending in 2025. Merck, the top spender at $15.7 billion, is followed by Johnson & Johnson, Astrazeneca, AbbVie, Eli Lilly, Pfizer, and Novartis each spending over $10 billion. The biotech industry, led by Amgen, decreased R&D spending by nearly 8% to $36 billion. Electromedical apparatus makers, led by Medtronic, spent a total of over $3.5 billion, an increase of 2% over 2024.
More on TelAve News
- Attorney Jason M. Sullivan Quoted in The Telegraph on Trump's $10 Billion BBC Lawsuit
- Sycamore Dove Releases "Loving Every Moment"
- Hospital Direct Medical Equipment Company Seeing Growth in Used Refurbished Medical Equipment Sales
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Nashville
- Soft & Sweet Unveils New Studio Location and Website for All-Natural Sugaring in Las Vegas
R&D budgets of semiconductor makers grew to over $93 billion, an increase of over 13%. Nvidia had the largest R&D budget, $18 billion, a 43% increase from 2024. Major suppliers to the infrastructure of the Internet cloud continue robust R&D spending to remain competitive.
The 2025 R&D spending of the automotive industry, led by Stellantis, Toyota, Honda, Ford and General Motors each spending over $8 billion, was up over 24% from the 2024 total with industry revenues up over 2%.
R&D Ratios & Budgets is an essential reference presenting R&D spending and intensity information published annually by Schonfeld & Associates, Inc. The study is based on 10-K annual report information submitted to the U.S. Securities & Exchange Commission.
R&D Ratios & Budgets contains information for each of the over 2,700 individual publicly traded companies. Fiscal year 2025 revenue and R&D spending are listed as well as annual growth rates of each. R&D intensity for 2025 is presented along with the lowest and highest R&D Intensity ratio during the past five years. The range of values gives an insight into the stability of the firm's commitment to funding R&D as well as its direction.
More on TelAve News
- Beyond Popularity Rankings, The World's No.1 Superstar® Wins Best Pop Music Video for "Under Your Spell"
- Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms
- ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection
- National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
- New England Consulting Partners Celebrates 25 Years of Turnaround Management Solutions
The industry summary section within R&D Ratios & Budgets presents for each of 280 industries: total fiscal year 2025 revenue and R&D spending as well as annual growth rates of each. The industry R&D intensity ratio for 2025 is listed so that an individual company's value can be compared to the value for the industry as a whole and to answer the question: Is this company leading or lagging its peers in prioritizing innovation?
To allow for further investigation, two Excel datafiles are available for purchase along with the PDF report. Each contains five years of revenue, R&D spending and R&D intensity information. One file contains company data and the other industry information.
The 2026 edition of the R&D Ratios & Budgets PDF study is $395 and the study along with Excel datafiles is $495. Contact Schonfeld & Associates, Inc., 1932 Terramar Lane, Virginia Beach, VA 23456. Call for more information or to place an order: 800-205-0030 or visit https://www.saibooks.com/product/r-d-ratios-budgets-2 for immediate download.
Source: Schonfeld & Associates, Inc.
0 Comments
Latest on TelAve News
- Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
- AI Agents Are Getting Their Own Computers. HRTech Leading in Vertical Harness Development
- UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology
- Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
- AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
- DayPass llega a ChatGPT y Claude
- DayPass launches in ChatGPT and Claude
- Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems
- Victor Archibong Expands ItsArchiDuh Creator Brand
- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
- Revinate launches hospitality's first data activation platform
- HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
- BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz
- Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
- Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
- Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
- Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
- Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
- BEC Technologies Introduces MX-320-UT 5G RedCap Router for Utility Grid Modernization
